Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23Andme Holding Co. (NQ: ME )

2.741 +0.181 (+7.09%)
Streaming Delayed Price Updated: 11:46 AM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,487,616
Open 2.630
Bid (Size) 2.740 (29)
Ask (Size) 2.750 (51)
Prev. Close 2.560
Today's Range 2.630 - 2.771
52wk Range 2.020 - 6.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Former SPACs I Still Own (And What I Think Now)
Remember the SPAC boom? Here are seven products of that time that are still in my portfolio. 
Via The Motley Fool
23andMe to Report FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via Globe NewsWire

Performance

YTD
+30.55%
+30.55%
1 Month
+30.55%
+30.55%
3 Month
-10.70%
-10.70%
6 Month
-17.18%
-17.18%
1 Year
-44.16%
-44.16%

More News

Read More
3 Penny Stocks That Could Make You Filthy Rich
Via The Motley Fool
My 4 Worst-Performing Stocks and What I Think Now
Via The Motley Fool
Guardant Health, Novavax And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
25 Meme Stocks to Sell Before They Die
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
The Worst Investment Decision I Made in 2022
Via The Motley Fool
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
From 23andMe Holding Co.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
Via Benzinga
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
Via TheNewswire.com
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
Via Benzinga
23andMe Reports FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via Globe NewsWire
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
From 23andMe Holding Co.
Via Globe NewsWire
A Preview Of 23andMe Holding's Earnings
Via Benzinga
I Bought 2 SPACs That Haven't Lived Up to Expectations -- Here's Why I'm Still Holding Them
Via The Motley Fool
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
From 23andMe Holding Co.
Via Globe NewsWire
23andMe to Report FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via Globe NewsWire
Bill Gates, Warren Buffett's Initiative For Billionaires To Donate Most Of Their Wealth Sees Sharp Drop In Pledgers In 2022
Via Benzinga
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
Via The Motley Fool
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via Globe NewsWire
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
From 23andMe Holding Co.
Via Globe NewsWire
7 Undervalued Reddit Stocks to Buy Before Wall Street Catches On
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.